Information Provided By: 
Fly News Breaks for February 22, 2019
REGN
Feb 22, 2019 | 07:32 EDT
As previously reported, Guggenheim analyst Yatin Suneja downgraded Regeneron Pharmaceuticals to Neutral after taking over coverage of the name, citing his belief that growth in its flagship Eylea product is abating and the launch of competitive products and biosimilars could lead to pricing pressure. The analyst lowered the price target for the shares to $425 from the firm's prior $466 target.
News For REGN From the Last 2 Days
REGN
Apr 26, 2024 | 08:41 EDT
Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.
REGN
Apr 25, 2024 | 07:28 EDT
